Roche Holding Company Profile (OTCMKTS:RHHBY)

About Roche Holding

Roche Holding logoRoche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: RHHBY
  • CUSIP:
Key Metrics:
  • Previous Close: $30.42
  • 50 Day Moving Average: $29.85
  • 200 Day Moving Average: $29.66
  • 52-Week Range: $25.25 - $33.77
  • Trailing P/E Ratio: 22.20
  • Foreward P/E Ratio: 14.99
  • P/E Growth: 2.35
  • Market Cap: $208.22B
  • Outstanding Shares: 6,815,701,000
  • Beta: 0.8
Additional Links:
Companies Related to Roche Holding:

Analyst Ratings

Consensus Ratings for Roche Holding (OTCMKTS:RHHBY) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Roche Holding (OTCMKTS:RHHBY)
Show:
DateFirmActionRatingPrice TargetDetails
5/13/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
1/22/2016Piper Jaffray CompaniesInitiated CoverageOverweightView Rating Details
10/20/2015Cowen and CompanyDowngradeOutperform -> Market Perform$42.00 -> $35.00View Rating Details
10/13/2015Credit Suisse GroupReiterated RatingOutperform$320.00View Rating Details
7/20/2015Baader BankUpgradeBuyView Rating Details
6/25/2015HSBC Holdings plcInitiated CoverageBuyView Rating Details
5/22/2015Erste GroupInitiated CoverageBuyView Rating Details
3/13/2015Liberum CapitalDowngradeHoldView Rating Details
(Data available from 3/1/2015 forward)

Earnings

Earnings History for Roche Holding (OTCMKTS:RHHBY)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Roche Holding (OTCMKTS:RHHBY)
Current Year EPS Consensus Estimate: $1.91 EPS
Next Year EPS Consensus Estimate: $2.03 EPS

Dividends

Dividend History for Roche Holding (OTCMKTS:RHHBY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Roche Holding (OTCMKTS:RHHBY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Roche Holding (OTCMKTS:RHHBY)
DateHeadline
finance.yahoo.com logoPhase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma (OTCMKTS:RHHBY)
finance.yahoo.com - February 18 at 8:19 AM
finance.yahoo.com logoRoche says Phase II trial supports twin treatment for kidney cancer (OTCMKTS:RHHBY)
finance.yahoo.com - February 18 at 8:19 AM
News IconU.S. Obtains Records in Lobbyist Probe -- WSJ (OTCMKTS:RHHBY)
ih.advfn.com - February 17 at 7:55 PM
investopedia.com logoRoche Hopes Drug Combo Will Save Herceptin Sales (OTCMKTS:RHHBY)
www.investopedia.com - February 15 at 12:50 AM
bloomberg.com logoRoche Fights Roche for $9 Billion Drug Business (OTCMKTS:RHHBY)
www.bloomberg.com - February 13 at 8:52 AM
finance.yahoo.com logoRoche Urges New Plan as Swiss Tax Vote Seen Slowing Investment (OTCMKTS:RHHBY)
finance.yahoo.com - February 13 at 8:52 AM
capitalcube.com logoRoche Holding AG :RHHBY-US: Earnings Analysis: For the six months ended December 31, 2016 : February 6, 2017 (OTCMKTS:RHHBY)
us.rd.yahoo.com - February 6 at 7:39 PM
capitalcube.com logoRoche Holding AG :RHHBY-US: Earnings Analysis: 2016 By the Numbers : February 3, 2017 (OTCMKTS:RHHBY)
www.capitalcube.com - February 3 at 10:52 PM
bloomberg.com logoRoche Sees Profit Growth Hiccup as Old Drug Guard Gets Replaced (OTCMKTS:RHHBY)
us.rd.yahoo.com - February 1 at 11:20 PM
us.rd.yahoo.com logoCompetition stalls Roche margin growth; drugmaker commits to diabetes unit (OTCMKTS:RHHBY)
us.rd.yahoo.com - February 1 at 11:20 PM
thestreet.com logoRoche Shares Gain; CEO 'Fully Dedicated' to Key U.S. Market (OTCMKTS:RHHBY)
us.rd.yahoo.com - February 1 at 11:20 PM
wsj.com logo[$$] Roche Unfazed by Trump's Drug-Price Comments (OTCMKTS:RHHBY)
us.rd.yahoo.com - February 1 at 11:20 PM
bloomberg.com logoRoche Considers Options for Diabetes Unit Including Sale (OTCMKTS:RHHBY)
www.bloomberg.com - January 31 at 9:57 PM
finance.yahoo.com logoRoche said to consider options for Diabetes unit- Bloomberg (OTCMKTS:RHHBY)
finance.yahoo.com - January 31 at 9:57 PM
feeds.reuters.com logoUPDATE 1-Roche said to consider options for Diabetes unit- Bloomberg (OTCMKTS:RHHBY)
feeds.reuters.com - January 31 at 5:19 PM
us.rd.yahoo.com logoRoche, Bristol-Myers Fight for Cancer Drug Market (OTCMKTS:RHHBY)
us.rd.yahoo.com - January 30 at 8:16 PM
News IconHere's the Best Dividend Stock in Big Pharma | Fox Business - Fox Business (OTCMKTS:RHHBY)
www.foxbusiness.com - January 30 at 1:01 AM
fool.com logoHere's the Best Dividend Stock in Big Pharma (OTCMKTS:RHHBY)
www.fool.com - January 29 at 8:24 AM
fool.com logoGuess Who Can't Wait for Trumpcare? (Hint: It's Not the Consumer) (OTCMKTS:RHHBY)
www.fool.com - January 29 at 8:23 AM
us.rd.yahoo.com logoA Would-Be Dividend Aristocrat With a 3.5% Dividend Yield (OTCMKTS:RHHBY)
us.rd.yahoo.com - January 24 at 9:31 PM
us.rd.yahoo.com logoFDA Grants Priority Review for Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis (OTCMKTS:RHHBY)
us.rd.yahoo.com - January 24 at 8:09 AM
thestreet.com logo[video]Is It Time to Buy Beaten-Down Bristol-Myers Squibb Stock? (OTCMKTS:RHHBY)
www.thestreet.com - January 23 at 8:59 AM
News IconBroker Changes For Roche Holding Ltd. (RHHBY) - NewsDen - NewsDen (OTCMKTS:RHHBY)
newsden.net - January 20 at 6:30 AM
rttnews.com logoFDA Says No To TSRO, Ablynx On Track, MYL Leads In Herceptin Biosim Race In U.S. (OTCMKTS:RHHBY)
www.rttnews.com - January 13 at 1:17 AM
thestreet.com logoEuropean Pharma Shares Hammered After Trump Press ... - TheStreet - TheStreet.com (OTCMKTS:RHHBY)
www.thestreet.com - January 12 at 8:12 PM
nasdaq.com logoRoche Gets Priority Review for Immunotherapy Drug Tecentriq - Nasdaq (OTCMKTS:RHHBY)
www.nasdaq.com - January 11 at 8:15 PM
us.rd.yahoo.com logoRoche Pharma Chief Sees Continued Pressure on Drug Prices (OTCMKTS:RHHBY)
us.rd.yahoo.com - January 10 at 9:30 PM
us.rd.yahoo.com logoRoche Gets Priority Review for Immunotherapy Drug Tecentriq (OTCMKTS:RHHBY)
us.rd.yahoo.com - January 10 at 9:30 PM
News IconRoche Holding Ltd. (RHHBY) Under Analyst Spotlight - UK Market News (OTCMKTS:RHHBY)
www.ukmarketnews.co.uk - January 9 at 8:17 PM
finance.yahoo.com logoRoche CEO: We’ll See Continued Pressure on Drug Prices (OTCMKTS:RHHBY)
finance.yahoo.com - January 9 at 8:16 PM
4-traders.com logoRoche : FDA approves Lucentis (ranibizumab injection) for myopic choroidal neovascularisation (OTCMKTS:RHHBY)
www.4-traders.com - January 6 at 8:34 PM
finance.yahoo.com logo3:19 am Roche Hldg receives clearance from FDA for Anti-Mllerian assay (OTCMKTS:RHHBY)
finance.yahoo.com - January 6 at 8:34 PM
finance.yahoo.com logoRoche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication (OTCMKTS:RHHBY)
finance.yahoo.com - January 6 at 8:34 PM
uk.finance.yahoo.com logoFDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization (OTCMKTS:RHHBY)
us.rd.yahoo.com - January 6 at 3:07 AM
finance.yahoo.com logoRoche gains FDA Clearance for 18-Minute Anti-Müllerian Hormone Test to Assess Ovarian Reserve (OTCMKTS:RHHBY)
finance.yahoo.com - January 6 at 3:07 AM
nasdaq.com logoMylan/Biocon's Herceptin Biosimilar Phase III Data Published - Nasdaq (OTCMKTS:RHHBY)
www.nasdaq.com - December 28 at 7:24 PM
zacks.com logoRoche (RHHBY) Hemophilia A Drug Positive in Phase III (OTCMKTS:RHHBY)
www.zacks.com - December 23 at 8:08 AM
finance.yahoo.com logoPharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe (OTCMKTS:RHHBY)
finance.yahoo.com - December 23 at 8:08 AM
finance.yahoo.com logoExelixis, Ipsen Amend Exclusive Agreement for Cabometyx (OTCMKTS:RHHBY)
finance.yahoo.com - December 22 at 7:53 PM
nasdaq.com logoRoche (RHHBY) MS Drug FDA Review Date Extended in U.S. - Nasdaq (OTCMKTS:RHHBY)
www.nasdaq.com - December 22 at 2:24 AM
us.rd.yahoo.com logoPositive Phase III Results of Genentech’s Investigational Medicine OCREVUS™ (Ocrelizumab) Published in New England Journal of Medicine (OTCMKTS:RHHBY)
us.rd.yahoo.com - December 21 at 9:24 PM
us.rd.yahoo.com logoFDA Extends Review of Application for OCREVUS™ (Ocrelizumab) (OTCMKTS:RHHBY)
us.rd.yahoo.com - December 20 at 2:12 PM
finance.yahoo.com logoU.S. extends review of Roche MS drug Ocrevus by three months (OTCMKTS:RHHBY)
finance.yahoo.com - December 20 at 2:12 PM
finance.yahoo.com logoRoche (RHHBY) to Terminate Pacifica Bioscience Agreement (OTCMKTS:RHHBY)
finance.yahoo.com - December 16 at 9:20 PM
us.rd.yahoo.com logoGrifols S.A. -- Moody's downgrades Grifols' CFR to Ba3 from Ba2, stable outlook (OTCMKTS:RHHBY)
us.rd.yahoo.com - December 16 at 12:35 AM
us.rd.yahoo.com logoRoche announces termination of 2013 Development, Commercialization and License Agreement with Pacific Biosciences (OTCMKTS:RHHBY)
us.rd.yahoo.com - December 16 at 12:35 AM
finance.yahoo.com logoMerck (MRK) Offers Update on Keytruda-Halaven Combination - Yahoo Finance (OTCMKTS:RHHBY)
finance.yahoo.com - December 14 at 8:04 AM
News IconRoche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval - Yahoo Sports (OTCMKTS:RHHBY)
sports.yahoo.com - December 14 at 8:04 AM
finance.yahoo.com logoOphthotech Hits 52-Week Low on Unfavorable Fovista Data - Yahoo Finance (OTCMKTS:RHHBY)
finance.yahoo.com - December 14 at 8:04 AM
us.rd.yahoo.com logoGeneric Version of Roche's Tamiflu Rolls Out in US (OTCMKTS:RHHBY)
us.rd.yahoo.com - December 12 at 7:37 PM

Social

What is Roche Holding's stock symbol?

Roche Holding trades on the OTCMKTS under the ticker symbol "RHHBY."

How do I buy Roche Holding stock?

Shares of Roche Holding can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Roche Holding stock cost?

One share of Roche Holding stock can currently be purchased for approximately $30.42.

Roche Holding (OTCMKTS:RHHBY) Chart for Wednesday, March, 1, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Roche Holding (OTCMKTS:RHHBY)

Earnings History Chart

Earnings by Quarter for Roche Holding (OTCMKTS:RHHBY)

Dividend History Chart

Dividend Payments by Quarter for Roche Holding (OTCMKTS:RHHBY)

Last Updated on 3/1/2017 by MarketBeat.com Staff